Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Holdings Lifted by Bank of America Corp DE

Bank of America Corp DE boosted its holdings in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 179.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 331,256 shares of the biopharmaceutical company’s stock after purchasing an additional 212,638 shares during the period. Bank of America Corp DE owned approximately 0.16% of Sangamo Therapeutics worth $338,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in SGMO. Schonfeld Strategic Advisors LLC acquired a new stake in Sangamo Therapeutics in the 4th quarter worth $1,744,000. Acuta Capital Partners LLC acquired a new stake in shares of Sangamo Therapeutics during the 4th quarter worth approximately $755,000. Boothbay Fund Management LLC acquired a new position in Sangamo Therapeutics during the fourth quarter valued at approximately $548,000. EAM Investors LLC bought a new position in Sangamo Therapeutics in the fourth quarter valued at approximately $256,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Sangamo Therapeutics in the fourth quarter worth $127,000. Hedge funds and other institutional investors own 56.93% of the company’s stock.

Sangamo Therapeutics Price Performance

Shares of SGMO opened at $0.49 on Friday. Sangamo Therapeutics, Inc. has a 1-year low of $0.30 and a 1-year high of $3.18. The firm’s 50 day simple moving average is $0.61 and its 200 day simple moving average is $1.09. The company has a market capitalization of $114.48 million, a P/E ratio of -0.65 and a beta of 1.19.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.03). The company had revenue of $6.44 million during the quarter, compared to the consensus estimate of $7.90 million. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. On average, equities analysts anticipate that Sangamo Therapeutics, Inc. will post -0.46 earnings per share for the current year.

Analyst Upgrades and Downgrades

SGMO has been the topic of a number of recent research reports. Barclays lowered their price target on shares of Sangamo Therapeutics from $9.00 to $5.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 14th. Royal Bank of Canada restated a “sector perform” rating and issued a $2.00 price target on shares of Sangamo Therapeutics in a research report on Tuesday, March 18th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Sangamo Therapeutics in a research note on Monday, April 7th. Finally, Wall Street Zen lowered shares of Sangamo Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, May 30th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $4.50.

Sangamo Therapeutics Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.